03-BMT-163: A Phase I, Open-Label, Dose-Escalating Study to Evluate the Safety, Tolerability and Immunogenicity of Recombinant Botulinum Vaccine A/B in Healthy Adults (rBV A/B-01)

Grants and Contracts Details

StatusFinished
Effective start/end date7/13/04 → 4/30/11

Funding

  • Covalent Group: $367,806.00